Showing 1 - 12 results of 12 for search 'Daniel P. Petrylak', query time: 0.05s
Refine Results
-
1
New developments in the treatment of castration resistant prostate cancer by Roxanne Wadia, Daniel P Petrylak
Published 2014-08-01
Article -
2
-
3
-
4
-
5
Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer by Tanya B. Dorff, Cathy M. Tangen, E. David Crawford, Daniel P. Petrylak, Celestia S. Higano, Derek Raghavan, David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson
Published 2009-09-01
Article -
6
Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advance... by Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Maria Matsangou, Chunzhang Wu, Mary Campbell, Mayumi Yamashiro
Published 2023-02-01
Article -
7
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RAN... by Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles
Published 2020-11-01
Article -
8
Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. by Piruz Motamedinia, Anna N Scott, Kendall L Bate, Neda Sadeghi, Guillermo Salazar, Edan Shapiro, Jennifer Ahn, Michael Lipsky, James Lin, Greg W Hruby, Ketan K Badani, Daniel P Petrylak, Mitchell C Benson, Michael J Donovan, Wayne D Comper, James M McKiernan, Leileata M Russo
Published 2016-01-01
Article -
9
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma by Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Published 2017-08-01
Article -
10
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma by Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg
Published 2016-12-01
Article -
11
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-res... by Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Published 2023-03-01
Article -
12
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial by Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Published 2022-08-01
Article